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Ovarian cancer is the ﬁfth leading cause of cancer death in women in North America, and approximately two-thirds of cases
of ovarian cancer are of high-grade serous type. The remaining cases are comprised of a mix of diﬀerent tumor types (e.g.,
endometrioid, clear cell, mucinous, etc.), with no single tumor type accounting for more than 10% of ovarian cancer cases.
These tumor types can be reproducibly diagnosed, and each features distinct underlying molecular events during oncogenesis,
with a characteristic natural history and response rate to conventional cytotoxic chemotherapy. In this review the molecular
abnormalities present in the more common non-high-grade serous subtypes of ovarian cancer will be presented. Development
of targeted therapies for these tumor types will require understanding of the genetic basis of each tumor type, and may lead to
subtype-speciﬁc therapy.
1.Introduction
Ovarian cancer is not a single disease but is comprised of
more than 15 distinct tumor types, each characterized by
subtype-speciﬁc risk factors (environmental and genetic),
precursor lesions, histopathological features, molecular
events during oncogenesis, response to chemotherapy, and
patient outcome [1, 2] (N.B. the terms “tumor type” and
“subtype” are used interchangeably in this paper to refer to
the morphologically deﬁned variants of ovarian cancer, as
diagnosed in routine surgical pathology practice). More than
90% of ovarian malignancies are carcinomas, commonly
referred to as surface epithelial carcinomas, even though
there are now signiﬁcant doubts about the cell of origin of
these tumors, and an increasing belief that many, if not most,
do not arise from ovarian surface epithelium. Of the group
of surface epithelial carcinomas (referred to hereafter simply
as carcinomas), approximately 70% are of high-grade serous
type [3].
High-gradeserouscarcinomasarechromosomallyunsta-
ble tumors, and usually have mutations in the TP53 tumor
suppressor gene [4]. In most cases they also have germline or
somaticmutationsinBRCA1orBRCA2,orpromotermethy-
lation of BRCA1 with loss of expression [5]. This underlying
loss of BRCA function and inability to repair double-strand
repair breaks, leading to chromosomal instability, are an
attractive therapeutic target for drugs that target DNA repair
(e.g., PARP inhibitors) [6–8].
There is an unfortunate tendency to use the terms
“ovarian cancer” and “high-grade serous carcinoma” inter-
changeably. While this is understandable, given high-grade
serous carcinomas account for most cases of ovarian cancer,
at least in North America and Europe, and most of the
deaths due to ovarian cancer, this has resulted in failure
to signiﬁcantly advance treatment for other ovarian cancer
subtypes, particularly the carcinoma subtypes. Although
it is current practice to treat all subtypes of carcinoma
with the same platinum/taxane chemotherapy, some sub-
types do not respond well to this approach and subtype-
speciﬁc trials of chemotherapy have been recommended
for clear cell and mucinous carcinoma in particular [9].
The large randomized clinical trials leading to reﬁnement
of the current chemotherapy for ovarian carcinoma have
been based on case series that, by current diagnostic
criteria, would be composed almost exclusively of high-
grade serous carcinomas, and none of these trials permit2 Journal of Oncology
any conclusions to be drawn about appropriate treatment
of other ovarian cancer subtypes. This minority of non-
high-grade serous ovarian cancers, consisting of a patch-
work of carcinoma subtypes and malignant tumors other
than those of surface epithelial type, will be a challenge
to study as there are relatively few cases of any given
subtype, and large mixed-case series are not appropriate
to explore targeted or subtype-speciﬁc therapies for these
subtypes.
Targeted therapy for ovarian carcinoma, if deﬁned as a
therapy directed speciﬁcally at molecular abnormalities in
individual tumors, will probably require consideration of the
tumor subtype, as the molecular abnormalities underlying
each of these subtypes are diﬀerent. The aim of this paper
is to present the most common subtypes of ovarian cancer
apart from high-grade serous type, discussing ﬁrst the
clinical signiﬁcance and then presenting an overview of
the molecular abnormalities for each subtype. This paper
does not cover histopathology, but an important point
is that, with recent advances in diagnostic criteria and
development of sensitive and speciﬁc immunomarkers, all
can be reproducibly diagnosed [2, 10]. This reproducibility
is recent and historical case series, or more recent ret-
rospective case series without contemporary slide review,
are not useful in understanding these uncommon tumor
subtypes as a signiﬁcant number of cases will have been
misclassiﬁed [10]. The frequency estimates for each subtype
are from our center (British Columbia Cancer Agency, which
serves a population of 4.1 million) [3], unless otherwise
indicated.
2. Endometrioid Carcinoma
Endometrioid carcinomas account for approximately 10% of
ovarian carcinomas, with most diagnosed at stage I or II.
Historical data on endometrioid carcinomas is not reliable
as many tumors that were diagnosed as endometrioid in the
past are now known to be high-grade serous carcinomas,
based on their immunoproﬁle [11]. Most endometrioid
carcinomas are grade 1 or 2 and there is a strong association
withendometriosis.Althoughoneofthemostcommonnon-
serous subtypes, because they are predominantly low stage
and low grade at presentation, the burden of morbidity and
mortality associated with this subtype is relatively low. While
there is a need for adjuvant chemotherapy for advanced-
stage endometrioid carcinomas, there is no data currently
available speciﬁcally on this subtype, and such data will be
hardtoaquiregiventhatadvanced-stageorrecurrenttumors
are rare.
The most common genetic abnormalities in endometri-
oid carcinoma are somatic mutations in the beta-catenin
(CTNNB1) and PTEN genes [12–14]. CTNNB1 mutations
are present in 38% to 50% of cases; mutations in codons
32, 33, 37, and 41, of exon 3, involve the phosphory-
lation sequence for glycogen synthase kinase 3-beta and
are thought to lead to decreased APC-mediated downreg-
ulation, with accumulation of beta-catenin protein in the
nucleus. Nuclear accumulation of beta-catenin protein can
(a)
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Figure 1: Ovarian carcinoma of endometrioid type (a). Immunos-
taining for beta-catenin shows both nuclear and membranous
localization within the tumor cells (b).
be demonstrated in 80% of cases (Figure 1); this contrasts
with the exclusively membranous localization seen in other
carcinoma subtypes. PTEN is mutated in approximately
20% of cases. BRCA abnormalities and loss of function
are not seen in endometrioid carcinomas. Endometrioid
carcinomas of the ovary are associated with hereditary
nonpolyposis colon cancer syndrome, in patients with
germline mutations in a gene encoding a DNA mismatch
repair enzyme. This results in microsatellite instability
in the tumor cells, which can also occur in sporadic
cases as a result of MLH1 promoter methylation. There
is coexistence of endometrioid carcinoma of ovary and
endometrium relatively frequently (up to 20% of cases of
endometrioid carcinoma of the ovary are associated with
synchronous atypical hyperplasia or endometrioid adeno-
carcinoma of the endometrium) [15, 16]. The favorable
outcome of such cases suggests that these are independent
primaries and also suggests a role of hormonal environment
in the genesis of endometrioid carcinoma of the ovary,
given the well-characterized role of unopposed estrogenic
stimulation as a risk factor for endometrial adenocarci-
noma of endometrioid type. Virtually all endometrioid
carcinomas of the ovary express estrogen receptor protein
[10].Journal of Oncology 3
3.ClearCellCarcinoma
Clear cell carcinomas occur at a similar frequency as
endometrioid carcinomas, and account for approximately
10%ofovariancarcinomasinNorthAmerica.Theyaremore
commoninJapan,atleastrelatively,althoughthismayreﬂect
only a proportional increase, with fewer high-grade serous
carcinomas. Clear cell carcinomas also usually present with
low-stage disease. All clear cell carcinomas are considered
high-grade [1], and they would all be treated with adjuvant
chemotherapy in most centers, because of a signiﬁcant
likelihood of relapse, but the available evidence suggests that
responses to adjuvant platinum/taxane chemotherapy are
uncommon [17–22]. The range of reported response rates is
wide (15%–45%), and it is likely that this reﬂects diﬀerences
in diagnostic accuracy historically, rather than biological
diﬀerences in cases series, although there is no proof of
this. Because of this poor response rate, and the relatively
aggressive nature of clear cell carcinoma, there is an acute
need for more eﬀective treatments. Clear cell carcinomas
were a subtype speciﬁcally mentioned at a recent National
Cancer Institute State of the Science meeting on ovarian
cancer as being a priority for subtype-speciﬁc trials of novel
therapeutic agents, in an attempt to identify more eﬀective
treatment [9].
The molecular origins of clear cell carcinomas remain
obscure. They are not associated with germline or somatic
BRCA mutations and typically do not show the complex
karyotypes associated with chromosomal instability [5];
most clear cell carcinomas are diploid or tetraploid (B.
Risberg and C. B. Gilks, unpublished data). Clear cell
carcinomas show relatively low-mitotic rates [5, 23], and
it is therefore not surprising that responses to agents
targeting dividing cells are less successful than those in
high-grade serous carcinoma. Clear cell carcinomas, like
endometrioid carcinomas, are strongly associated with
the presence of endometriosis and are not uncommonly
seen arising in endometriotic cysts. Unlike endometrioid
carcinomas, however, they lack expression of hormone
receptors (estrogen receptor or progesterone receptor) [24],
suggesting that the hormonal inﬂuence during oncogenesis
is diﬀerent; clear cell carcinomas may be analgous to the
nonhormonally dependent Type 2 endometrial carcinomas
while endometrioid carcinomas share many features (both
morphological and molecular) with Type 1 carcinomas of
the endometrium [25]. Clear cell carcinomas of the ovary
showstrikingsimilaritiestorenalclearcellcarcinomas,based
on gene expression proﬁling [26], raising the possibility
that responses to treatment could be similar in clear cell
carcinomas arising at diﬀerent sites. To investigate this
possibility, we treated mice carrying xenografts of an ovarian
clear cell carcinoma with sunitinib, a kinase inhibitor that
targets VEGF action that is approved for use in patients with
renal clear cell carcinoma, and demonstrated a response to
sunitinib in the clear cell carcinoma xenograft but not in
xenografts derived from three diﬀerent high-grade serous
carcinomas (Y. Z. Wang and C. B. Gilks, unpublished data).
Clear cell carcinomas have not been speciﬁcally studied for
sensitivity to agents targetting angiogenesis/VEGF in human
Figure 2: HER2 immunostaining of a mucinous carcinoma shows
diﬀuse membranous positivity. This was associated with high-level
HER2 ampliﬁcation on FISH analysis.
patients, but this may prove to be a fruitful avenue of
study. Interestingly, there is evidence that ovarian clear cell
carcinomasaresensitivetoradiotherapy[27];giventhatclear
cellcarcinomasarenotrapidlyproliferatingtumors,thismay
reﬂect targetting of intratumoral neovascularization by the
radiotherapy.
4. MucinousCarcinoma
Mucinous carcinomas are much less common than was
previously thought, as historically many case series included
cases of metastic carcinoma with mucinous diﬀerentiation,
that were primary in gastrointestinal or biliary tract. Only
3%-4% of ovarian carcinoma are of mucinous type and
most are conﬁned to the ovary at presentation. Nonetheless,
some will recur and when they do, there are no eﬀective
treatments. Mucinous carcinomas, like clear cell carcinomas,
were singled out as being a priority for subtype-speciﬁc
clinical trials, given the ineﬀectiveness of current therapy [9].
Mutations in KRAS, involving codons 12 and 13, are the
mostcommonmutationsdescribedinmucinouscarcinomas
[28]. Mutations can be seen in benign-appearing areas of
mucinous tumors, adjacent to frank mucinous carcinoma,
suggesting that they are an early event during oncogenesis.
HER2 ampliﬁcation, with overexpression of the protein on
the membrane of the tumor cells, is present in 15%–20%
of mucinous carcinomas of the ovary (J. N. McAlpine et al.
BMC Cancer, in press.) (Figure 2). This is a higher frequency
of HER2 ampliﬁcation than is seen in breast cancer, and it
is similar to the frequency encountered in adenocarcinoma
of the gastroesophageal junction. Trastuzumab (Herceptin)
therapy is an obvious treatment choice for these cases but
there is no data yet on response of mucinous carcinomas
of the ovary with HER2 ampliﬁcation/overexpression to
such treatment. Although there are large clinical trials of
trastuzumab therapy in ovarian cancer, with discouraging
results, almost all tumors in these studies were of high-
g r a d es e r o u st y p e[ 29]. High-grade serous carcinomas only
rarely show high-level ampliﬁcation of the HER2 gene
or overexpression of HER2 protein on the cytoplasmic4 Journal of Oncology
membrane of tumor cells [30], and these studies are not
informative about eﬃcacy of this therapeutic option in
mucinous carcinoma.
5. Low-Grade Serous Carcinoma
The separation of serous carcinomas into low-grade and
high-grade types is a recent development. Comparison of
low-grade and high-grade serous carcinomas shows that
the low-grade serous carcinomas often arise from a serous
borderline tumor while the precursor lesion of high-grade
serous carcinoma is tubal intraepithelial carcinoma, in most
cases. Low-grade serous carcinomas can be reproducibly
distinguished from high-grade serous carcinomas, based pri-
marilyontheirveryuniformnuclei,usinglow-mitoticrateas
a secondary diagnostic criterion [31, 32]. Low-grade serous
carcinomas are much less common than high-grade serous
carcinomas and account for only 2% of ovarian carcinomas.
As many present with high-stage disease, however, there is
a need for eﬀective chemotherapy. An unusual feature of
the natural history of low-grade serous carcinomas is that
they may follow a relatively indolent course; this in turn
allows for multiple opportunities to treat [33]. The response
rate to platinum/taxane chemotherapy within this group is
diﬃcult to gauge, as there are no studies of large series of
well-characterized cases. In the case of serous borderline
tumorsthathaveprogressedtolow-gradeserouscarcinomas,
however, response rates are relatively low, with most patients
showing no response [34]. As is the case for clear cell
c a r c i n o m a s ,l o w - gra d es e r o u sc a r c i n o m a sh a v eal o w - m i t o t i c
rate, and poor response to platinum-based chemotherapy is
not unexpected.
KRAS or BRAF mutations, which target the same
molecular pathway, are present in most low-grade serous
carcinomas [35–37]. These tumors are also almost invariably
positive for hormone receptor expression (estrogen and/or
progesterone receptors). Low-grade serous carcinomas are
not chromosomally unstable; they are usually diploid or near
diploid and do not show the complex genetic abnormalities
seeninhigh-gradeserouscarcinomas[38].Low-gradeserous
carcinomas are not associated with either germline or
somatic abnormalities in BRCA1/2 and typically do not
have TP53 mutations. Only rarely do low-grade serous
c a r c i n o m a sp r o g r e s st oh i g h e r - g r a d et u m o r s[ 39].
6.GranulosaCellTumor
Granulosa cell tumors are the most common malignant
tumors within that group of tumors arising from ovarian
sex cord or stromal cells, and account for a large majority
of the malignant tumors within this category [1]. They
are still relatively uncommon, and have been reported
to account for approximately 1%-2% of ovarian tumors
(benign or malignant), although in our experience this
is an overestimate. They may account for 2% of ovarian
cancers, however. They are the most common primary
ovarian malignancies, apart from carcinomas. As with some
of the other subtypes discussed above, they have not been
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Figure 3: Results of sequencing of the transcriptome of a granulosa
cell tumor, showing sequence from the FOXL2 gene (a). At
nucleotide 402, both G and C were identiﬁed, indicating that this
tumor was hemizygous for the 402C->G mutation charateristic
of adult-type granulosa tumor. Granulosa tumor cell nuclei show
high-level expression of the FOXL2 protein by immunostaining (b),
in association with this mutation.
reliably diagnosed in the past, so that older data regarding
their natural history or molecular abnormalities is not
reliable. There are two distinct granulosa cell variants and
the discussion that follows relates only to the adult-type
granulosa cell tumors, which account for 95% of granulosa
cell tumors. These tumors are usually conﬁned to the ovary
at presentation, and recurrences can be many years after
presentation [1]. The only eﬀective therapeutic option at
present is surgery.
Granulosacelltumorsaregenomicallystableanddiploid.
They show few abnormalities by cytogenetic analysis. It
is likely that some tumors considered to be aneuploid
granulosa cell tumors in the past were undiﬀerentiated
carcinomas, based on their natural history (early recurrence
and poor prognosis). Recently 4 granulosa cell tumors were
subjected to transcriptome sequencing, revealing a missense
G > C mutation at nucleotide 402 of the FOXL2 gene
in every case (Figure 3)[ 40]. Extension of this study by
examination of additional cases revealed that these identical
402G->C FOXL2 mutations were present in more than 95%
of cases diagnosed as adult-type granulosa cell tumors, as
well as occasional thecomas, and a single juvenile granulosa
cell tumor (of ten tested) [40]. It is likely that at least
two of the three cases of purported adult-type granulosa
cell tumor lacking an FOXL2 mutation were misdiagnosedJournal of Oncology 5
and were not granulosa cell tumors, based on a review
of the tumor’s immunophenotypes, while the thecomas
showing the FOXL2 mutation did have minor granulosa cell
components, on retrospective review of the cases.
The FOXL2 gene is a member of the forkhead/winged-
helix family of transcription factors, and this point mutation
results in a cysteine to tryptophan change at position 134 in
the amino acid sequence of the protein, a highly nonconser-
vative change, which is predicted to aﬀect protein-protein
interactions. FOXL2 is a crucially important transcription
factor in granulosa cell development; an autosomal reces-
sive disorder, blepharophimosis-ptosis-epicanthus inversus
syndrome, occurring as a result of two mutant alleles
of FOXL2, is associated with ovarian failure [41–43]. In
granulosa cell tumors, the FOXL2 mutations are somatic; in
all cases tested, the germline sequence has been normal. The
near universal presence of this FOXL2 mutation in adult-
type granulosa cell tumors, the fact that most tumors are
hemizygous for the mutation, and the presence of abundant
FOXL2 protein in tumor cell nuclei (Figure 3)s u g g e s t
that this mutation is a critical genetic abnormality in the
genesis of adult-type granulosa cell tumors and that it is an
activating mutation. FOXL2 interacts with SMAD and AP1
proteins, and it is possible that this interaction is disrupted,
leading to uncontroled growth. The presence of a single
mutation suggests the possibility of targeted therapy, similar
to what has been developed for other cancers where speciﬁc
recurrent genetic abnormalities are present (e.g., chronic
myelogenous leukemia, gastrointestinal stromal tumor, and
dermatoﬁbrosarcoma protuberans).
7. Dysgerminoma
Dysgerminomas are within the group of primitive germ cell
tumors, which are deﬁned as malignant, nonteratomatous
germ cell tumors [1]. Dysgerminomas are morphologically
indistinguishable from their much more common counter-
partinthemale,testicularseminoma.Althoughdysgermino-
mas are the most common of the primitive germ cell tumors
of the ovary, they are rare and account for less than 1% of
ovarian cancers. These tumors are chemosensitive, and most
patients, even with advanced-stage disease at presentation,
can be cured.
The genetic abnomormalities in dysgerminoma are iden-
tical to those of seminoma. Cytogenetically, abnormalities
of chromosome 12, particularly i(12p), are commonly
present [44]. Activating mutations in KIT are present in
a signiﬁcant minority of patients with dysgerminoma and
are associated with high-level expression of KIT protein in
the tumor cells [45–47]. KIT protein can also be present in
dysgerminomas without an identiﬁable KIT mutation; the
mechanism underlying KIT overexpression in these cases is
not known.
8. Summary
Although there has been progress in elucidating the molec-
ular basis of the less common subtypes of ovarian cancer,
there remains much work to be done if targeted therapy is
to become a routine option clinically. There are compounds
available that can target some of the molecular abnormalities
identiﬁed (HER2 ampliﬁcation in mucinous carcinoma,
neovascularization and VEGF signaling in clear cell carci-
noma,hormonereceptorsignalinginlow-gradeserouscarci-
noma, and KIT mutations in dysgerminoma); future studies
should focus on both identiﬁcations of additional targets;
rational preclinical studies and subtype-speciﬁc clinical trials
of targeted therapies aimed at promising molecular targets.
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